NGLFINE
NSENGL Fine-Chem Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹3,048.80
332.30 (12.23%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹1.88K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
34.9
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹980+211.1%
52W High₹3,144-3.0%
Current Price
₹3,048.80
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹2,439.04
Upper Circuit₹3,658.56
Reference Price
₹3,048.80
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1451.6
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹2691.0
Composite score 60.66 (STRONG_BUY) with 87.4% confidence
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Volume divergence: Bearish (price up, volume down)
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
87%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
2670.59
EMA50
2485.29
EMA200
1936.99
Price Action
MIXED
NEUTRAL
Higher Highs3
Higher Lows4
Lower Highs6
Lower Lows5
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹3005.00
₹2767.90
₹2566.67
₹2497.00
₹2433.67
Volume Analysis
TrendDECREASING
Change-14.30%
Unusual Volume
Yes (3.44x avg)
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹3018.31
3% Risk₹2957.34
5% Risk₹2896.36
7% Risk (Custom)
₹2835.38Technical Levels
1x ATR (Volatility)₹2829.20
2x ATR (Swing)₹2609.60
3x ATR (Trend)₹2390.00
Immediate Support₹3005.00
Moving Averages
EMA 9 (Short-term)₹2782.42
EMA 20 (Medium-term)₹2670.59
EMA 50 (Trend)₹2485.29
EMA 200 (Long-term)₹1936.99
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹89.7 Cr | ₹104.2 Cr | ₹120.3 Cr | ₹127.5 Cr |
| Net Profit | ₹82,40,000 | ₹9.2 Cr | ₹9.6 Cr | ₹15.7 Cr |
| EPS | — | ₹14.96 | ₹15.58 | ₹25.40 |
| Operating Profit | ₹5.6 Cr | ₹17.3 Cr | ₹19.2 Cr | ₹26.9 Cr |
ROE
7.48%
ROCE
8.36%
Debt/Equity
0.27
Current Ratio
1.98
OPM
21.12%
NPM
12.31%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 12 Aug 2025 | Dividend - Rs 1.75 Per Share | DIVIDEND |
| 16 Aug 2024 | Annual General Meeting/Dividend - Rs 1.75 Per Share | AGM |
| 18 Aug 2023 | Annual General Meeting/Dividend - Rs 1.75 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for NGLFINE
View AllNEWS
positive
Business Standard - Markets 22d ago
NGL Fine Chem consolidated net profit rises 2398.15% in the March 2026 quarter
Sales rise 57.13% to Rs 149.23 crore
NGLFINEHealthcare
NEWS
negative
Business Standard - Markets 36d ago
Rossell Techsys Ltd leads losers in 'B' group
NGL Fine Chem Ltd, Globus Spirits Ltd, Team India Guaranty Ltd and STL Networks Ltd are among the other losers in the BSE's 'B' group today, 08 May 2026.
BSEGLOBUSSPRNGLFINEROSSELLINDROSSTECHSGLSTLNETWORKTEAMGTYCapital GoodsFast Moving Consumer Goods
NEWS
positive
Business Standard - Markets 89d ago
Nidhi Granites announces sale of stepdown subsidiary - Fine Papyrus
SPNP Paper and Pack, a wholly owned subsidiary of Nidhi Granites, has entered into a Share Purchase Agreement dated 16 March 2026 with NGL Corporation for the sale of its 100% shareholding in Fine Papyrus, which is a step-down subsidiary of the Company.
JKPAPERNGLFINEForest MaterialsHealthcare